IMCIVREE (Setmelanotide), Drug Insight and Market Forecast - 2032

“IMCIVREE (Setmelanotide), Drug Insight and Market Forecast - 2032” report provides comprehensive insights about IMCIVREE (Setmelanotide) for Obesity in the 7MM. A detailed picture of the IMCIVREE (Setmelanotide) for Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the IMCIVREE (Setmelanotide) for Obesity. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the IMCIVREE (Setmelanotide) market forecast, analysis for Obesity in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Obesity.

Drug Summary

IMCIVREE is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The condition must be confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).It is administered subcutaneously.

Setmelanotide is an MC4 receptor agonist with 20-fold less activity at the melanocortin 3 (MC3) and melanocortin 1 (MC1) receptors. MC4 receptors in the brain are involved in the regulation of hunger, satiety, and energy expenditure. In patients with obesity due to POMC, PCSK1, and LEPR deficiency associated with insufficient activation of the MC4 receptor, setmelanotide may re-establish MC4 receptor pathway activity to reduce hunger and promote weight loss through decreased caloric intake and increased energy expenditure. Nonclinical evidence shows that MC4 receptors are important for setmelanotide-regulated appetite and weight loss. The MC1 receptor is expressed on melanocytes, and activation of this receptor leads to the accumulation of melanin and increased skin pigmentation independently of ultraviolet light.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the IMCIVREE (Setmelanotide) description, mechanism of action, dosage and administration, research and development activities in Obesity.
• Elaborated details on IMCIVREE (Setmelanotide) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the IMCIVREE (Setmelanotide) research and development activity in Obesity in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around IMCIVREE (Setmelanotide).
• The report contains forecasted sales of IMCIVREE (Setmelanotide) for Obesity till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Obesity.
• The report also features the SWOT analysis with analyst views for IMCIVREE (Setmelanotide) in Obesity.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMCIVREE (Setmelanotide) Analytical Perspective

In-depth IMCIVREE (Setmelanotide) Market Assessment

This report provides a detailed market assessment of IMCIVREE (Setmelanotide) in Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

IMCIVREE (Setmelanotide) Clinical Assessment

The report provides the clinical trials information of IMCIVREE (Setmelanotide) in Obesity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Obesity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMCIVREE (Setmelanotide) dominance.
• Other emerging products for Obesity are expected to give tough market competition to IMCIVREE (Setmelanotide) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMCIVREE (Setmelanotide) in Obesity.
• The in-depth analysis of the forecasted sales data of IMCIVREE (Setmelanotide) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the IMCIVREE (Setmelanotide) in Obesity.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of IMCIVREE (Setmelanotide)?
• What is the clinical trial status of the study related to IMCIVREE (Setmelanotide) in Obesity and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMCIVREE (Setmelanotide) development?
• What are the key designations that have been granted to IMCIVREE (Setmelanotide) for Obesity?
• What is the forecasted market scenario of IMCIVREE (Setmelanotide) for Obesity?
• What are the forecasted sales of IMCIVREE (Setmelanotide) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Obesity and how are they giving competition to IMCIVREE (Setmelanotide) for Obesity?
• Which are the late-stage emerging therapies under development for the treatment of Obesity?

This product will be delivered within 2 business days.